The Swiss pharmaceutical company Roche is putting all future investment decisions in Germany on hold for the time being. This move is prompted by the German federal government’s austerity measures in the healthcare sector, which the company views as a significant economic burden. Roche is particularly critical of the planned additional mandatory rebates that manufacturers must provide on pharmaceutical products. The group employs more than 18,000 people in Germany and has invested billions in its local sites to date. While projects that have already been approved will continue, no new investment decisions are being made for the time being. Consequently, these austerity measures jeopardize future industrial investment and the creation of new jobs within Germany’s pharmaceutical sector in the long term.
Image: Shutterstock
Roche criticizes the German federal government’s austerity policy
Daniel Steiners, head of Roche in Germany, explains that this decision stems from a massive loss of trust in the government. In its coalition agreement, the federal government had pledged to strengthen Germany as a hub for the pharmaceutical industry. At the same time, however, it is seeking to achieve further savings on pharmaceuticals through the “Statutory Health Insurance Contribution Rate Stabilization Act” (GKV-Beitragssatzstabilisierungsgesetz). Steiners criticizes the government for pursuing short-term budgetary relief at the expense of the industry.
According to the company, higher manufacturer rebates do not resolve the structural financial problems of the statutory health insurance system. Instead, they worsen the economic conditions for pharmaceutical manufacturers. Roche is therefore calling for long-term, reliable political framework conditions and fundamental reforms. In Steiners’ view, the relief measures proposed for research-based companies are insufficient.
Billions in investments and over 18,000 employees
This decision concerns one of the most significant investors in the German pharmaceutical industry. In 2025 alone, Roche invested approximately 719 million euros in its German sites. Since 2020, a total of about 3.8 billion euros has been channeled into Germany. The production and research facilities in Mannheim and Penzberg are of particular importance.
In Penzberg, a new diagnostics production center is currently being built at a cost of over 600 million euros. In Mannheim, the company is also investing in modern logistics and production infrastructure. These projects, which have already been approved, will continue despite the current decision. However, new initiatives will not be granted investment approval for the time being. Roche has not yet announced any specific plant closures or job cuts.
Roche follows other pharmaceutical investors in scaling back
Other international pharmaceutical corporations have also recently reduced or called into question their investment plans for Germany. The US-based company Eli Lilly has significantly curtailed planned projects in Rhineland-Palatinate. Boehringer Ingelheim has likewise scrapped planned investments, while Pfizer is currently reviewing further projects. Among other concerns, these companies cite unfavorable economic conditions and additional burdens resulting from healthcare policy.
This intensifies international competition for new research and production sites. When making investment decisions, pharmaceutical companies often consider time horizons spanning decades; therefore, stable legal frameworks and economically viable business models play a crucial role. In this regard, Germany is competing primarily with the United States and China—both of which offer large consumer markets and, in some cases, more favorable investment conditions.
Federal government’s investment summit overshadowed by Roche’s decision
The timing of this announcement is particularly inconvenient for the federal government. Chancellor Friedrich Merz is currently hosting an investment summit in Berlin, where he is seeking to attract additional capital to Germany as a business location. At the same time, a long-standing major investor is putting its future investment decisions on hold. This creates a clear contradiction between political growth targets and the experience of a significant industrial enterprise.
Roche has been present in Germany for around 130 years and has continuously expanded its sites. However, this long-standing presence does not guarantee future investments. Consequently, CEO Steiners explicitly points to the competition from the United States and China. International companies are increasingly allocating new projects based on economic criteria related to the business location. In this context, Germany must compete against other industrial and research hubs.
Economic Policy Promises Are Not Enough to Secure Investment
Through its austerity measures, the German federal government aims to curb the rising costs of the statutory health insurance system. However, placing additional financial burdens on pharmaceutical manufacturers may also diminish their willingness to invest. This creates a conflict between different economic policy objectives: short-term savings in the healthcare sector can, in the long run, impair investments in research, development, and production.
The consequences of such a decline in investment extend well beyond individual companies. New research centers, production facilities, and industrial jobs only materialize when companies commit sufficient capital. If such investments fail to materialize, competing economic locations may stand to benefit instead. The move by Roche therefore illustrates just how directly political decisions influence industrial investment planning. Whether the company will move past its current reticence now depends, in large part, on the future regulatory and economic framework.
Author: Blackout News
Sources: EuroNews (20.10.26) – Reuters (19.10.26) – Deutsches Ärzteblatt (19.10.26)